TW202128747A - ＴＧＦ－β－ＲＩＩ結合蛋白 - Google Patents

ＴＧＦ－β－ＲＩＩ結合蛋白 Download PDF

Info

Publication number
TW202128747A
TW202128747A TW109145819A TW109145819A TW202128747A TW 202128747 A TW202128747 A TW 202128747A TW 109145819 A TW109145819 A TW 109145819A TW 109145819 A TW109145819 A TW 109145819A TW 202128747 A TW202128747 A TW 202128747A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
amino acid
acid sequence
sequence shown
Prior art date
Application number
TW109145819A
Other languages
English (en)
Chinese (zh)
Inventor
馬克 索斯拜
Original Assignee
荷蘭商美勒斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷蘭商美勒斯公司 filed Critical 荷蘭商美勒斯公司
Publication of TW202128747A publication Critical patent/TW202128747A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109145819A 2019-12-24 2020-12-23 ＴＧＦ－β－ＲＩＩ結合蛋白 TW202128747A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
NL2024576 2019-12-24

Publications (1)

Publication Number Publication Date
TW202128747A true TW202128747A (zh) 2021-08-01

Family

ID=69700252

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109145819A TW202128747A (zh) 2019-12-24 2020-12-23 ＴＧＦ－β－ＲＩＩ結合蛋白
TW112150430A TW202417513A (zh) 2019-12-24 2020-12-23 TGF-β-RII結合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112150430A TW202417513A (zh) 2019-12-24 2020-12-23 TGF-β-RII結合蛋白

Country Status (13)

Country Link
US (1) US12570747B2 (enExample)
EP (2) EP4081306A1 (enExample)
JP (3) JP7633259B2 (enExample)
KR (2) KR20230145542A (enExample)
CN (3) CN115038497A (enExample)
AR (2) AR120914A1 (enExample)
AU (2) AU2020412201B2 (enExample)
BR (1) BR112022012522A2 (enExample)
IL (2) IL294181A (enExample)
MX (2) MX2022007919A (enExample)
PH (1) PH12022551527A1 (enExample)
TW (2) TW202128747A (enExample)
WO (1) WO2021133167A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7633259B2 (ja) * 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質
CN118265725A (zh) * 2021-11-19 2024-06-28 美勒斯公司 包含PD-1和TGF-βRII结合域的多特异性结合部分
CN121736114A (zh) 2022-12-20 2026-03-27 美勒斯公司 FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
PE20140982A1 (es) 2011-01-06 2014-08-22 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
JP7633259B2 (ja) * 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質

Also Published As

Publication number Publication date
MX2022007919A (es) 2022-07-27
EP4269433A3 (en) 2024-05-22
IL294181A (en) 2022-08-01
TW202417513A (zh) 2024-05-01
IL304317A (en) 2023-09-01
JP7633259B2 (ja) 2025-02-19
AU2023200779A1 (en) 2023-03-09
AR130991A2 (es) 2025-02-05
BR112022012522A2 (pt) 2022-09-06
JP2023076596A (ja) 2023-06-01
JP2023508202A (ja) 2023-03-01
EP4269433A2 (en) 2023-11-01
AU2020412201B2 (en) 2026-02-12
CN115038497A (zh) 2022-09-09
KR20220117267A (ko) 2022-08-23
PH12022551527A1 (en) 2024-01-29
EP4081306A1 (en) 2022-11-02
KR20230145542A (ko) 2023-10-17
AU2023200779B2 (en) 2026-02-19
CN116199780A (zh) 2023-06-02
AR120914A1 (es) 2022-03-30
MX2024002182A (es) 2024-05-03
US20250270331A1 (en) 2025-08-28
JP2025083342A (ja) 2025-05-30
WO2021133167A1 (en) 2021-07-01
AU2020412201A1 (en) 2022-07-14
US12570747B2 (en) 2026-03-10
CA3165605A1 (en) 2021-07-01
CN116375869A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
KR20210093255A (ko) 항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
AU2023200779B2 (en) TGF-beta-RII binding proteins
US20230071422A1 (en) ANTI-CD3 and ANTI-CD123 Bispecific Antibody and Use Thereof
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2021516537A (ja) Ｃ−ｍｅｔ結合剤
CN110615840A (zh) 全人源的抗lag-3抗体及其应用
JP2021515544A (ja) Ｅｒｂｂ３結合剤
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
CA3165605C (en) Tgf-beta-rii binding proteins
TW202302630A (zh) 新穎多特異性抗體
HK40094429A (en) Tgf-beta-rii binding proteins
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
EA051539B1 (ru) Белки, связывающие tgf-бета-rii
TW202430547A (zh) 結合至nkg2a及pd-l1之藥劑及其用途
TW202413414A (zh) 抗ｉｌｔ４抗體及其醫藥用途
TW202436338A (zh) Nkg2a結合劑及其用途
WO2026008055A1 (zh) 抗kit抗体及其医药用途
WO2025025190A1 (zh) 抗cd73抗体及其应用
HK40066221B (zh) 人源化抗vegf fab抗体片段及其用途
HK40066221A (zh) 人源化抗vegf fab抗体片段及其用途